title: [Human GDNF cDNA-engineered SH-SY5Y cells' neurotrophic and protective effect on primary dopaminergic neurons of rat].
abstract: OBJECTIVE
  To construct a kind of engineered cell secreting human GDNF and study its possible effects on gene therapy of Parkinson's disease.
  
  
  METHODS
  Human GDNF cDNA with Kozak sequence was cloned by RT-PCR, and then was transfected into SH-SY5Y cell line of human neuroblastoma. These engineered cells were co-cultured with primary mesencephalic cells of rats. Dopaminergic neurons were examined by immunohistochemistry.
  
  
  RESULTS
  The number of dopaminergic neurons protected by engineered cells increased at least by 95.4% in comparison with the control cells (P < 0.01). The number of dopaminergic neurons protected by engineered cells against MPP+ toxicity increased 9.5-10.8 times (P < 0.01).
  
  
  CONCLUSIONS
  A kind of engineered SH-SY5Y cells secreting human GDNF has been constructed successfully. These cells obviously protect dopaminergic neurons against degeneration and MPP+ toxication and may play an important role in gene therapy of Parkinson's disease.
authors.affiliation: Neuroscience Research Institute, Peking University, Beijing 100083, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
mesh_terms: D015655:1-Methyl-4-phenylpyridinium / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D002478:Cells, Cultured; D018920:Coculture Techniques; D018076:DNA, Complementary / Q000235:genetics; D004298:Dopamine / Q000502:physiology; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D008636:Mesencephalon / Q000166:cytology; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000494:pharmacology*; D009447:Neuroblastoma; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D010300:Parkinson Disease / Q000628:therapy; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D018076:DNA, Complementary; C495039:GDNF protein, human; C495041:Gdnf protein, rat; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D020011:Protective Agents; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine